Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 20,894,809.49, representing a growth of 20.58% year-on-year[9] - Operating revenue for the first quarter of 2023 was CNY 81,091,529.35, up 3.07% from the same period last year[9] - Total operating revenue for Q1 2023 reached ¥81,091,529.35, an increase of 3.6% compared to ¥78,677,625.48 in Q1 2022[58] - Total profit reached CNY 23,799,155.91, up from CNY 19,841,045.10, indicating a growth of approximately 19.7%[63] - Operating profit slightly decreased to CNY 18,864,589.14 from CNY 19,833,123.92, a decline of about 4.9%[63] - Basic and diluted earnings per share for Q1 2023 were both ¥0.08, up from ¥0.06 in Q1 2022[60] - The company reported a significant increase in interest income to CNY 1,687,597.44 from CNY 1,188,495.23, representing a growth of approximately 42%[63] - Net profit rose to CNY 20,889,136.99, compared to CNY 17,322,251.00, marking an increase of about 20.5% year-over-year[64] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 14,410,166.78, a decrease of 9283.03% compared to the previous year[13] - Cash flow from investment activities showed a net outflow of CNY 50,994,104.00, a significant increase of 539.85% compared to the previous year[13] - The net cash flow from operating activities was -14,415,846.86, a significant decrease compared to 149,774.03 from the previous period, indicating a decline in operational efficiency[68] - The total cash outflow from operating activities was 76,338,631.09, which is an increase from 61,643,415.40 in the previous period, indicating rising operational costs[68] - The company faced a net cash outflow of 50,994,104.00 from investing activities, highlighting a focus on capital expenditures despite the negative cash flow[68] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 881,274,401.64, an increase of 1.42% compared to the end of the previous year[9] - The total liabilities to assets ratio remained stable at 19.30% for both the parent and consolidated entities[9] - Total liabilities decreased to ¥170,113,880.59 from ¥172,771,172.59, a reduction of approximately 1.53%[52] - Total equity attributable to shareholders rose to ¥711,160,521.05 from ¥696,141,073.57, an increase of approximately 2.16%[52] - Total non-current assets decreased to ¥244,289,161.03 from ¥251,674,448.53, a decline of about 2.94%[51] - Cash and cash equivalents decreased to ¥257,183,751.02 from ¥293,867,101.54, a decline of about 12.5%[50] Shareholder Information - The total number of shareholders as of the report date was 3,426[17] - The company reported a total share repurchase of 3,055,980 shares, accounting for 1.12% of the total share capital, with a total expenditure of approximately ¥24.60 million, representing 57.09% of the planned repurchase fund limit[31] - The company has a significant shareholder structure, with the largest shareholder holding 39.06% and the second-largest holding 19.71%[22] - The company has successfully implemented its share repurchase plan, achieving 84.89% of the planned repurchase quantity[31] Legal and Compliance - The company is involved in two non-significant lawsuits with a total claim amount of ¥4.98 million, currently in the execution phase[27] - The company has not reported any significant external guarantees or loans during the reporting period[26] - The company has no reported cases of asset seizure, freezing, or other significant legal issues during the reporting period[26] - Major shareholders have signed commitments to avoid competition, which were fulfilled without any violations during the reporting period[33] - Commitments to avoid fund occupation by major shareholders were adhered to without any breaches in the reporting period[34] - The company has maintained compliance with commitments to regulate related party transactions, with no violations reported[35] Research and Development - Research and development expenses for Q1 2023 were ¥6,647,428.05, up from ¥5,504,816.75 in Q1 2022, indicating an increase of 20.7%[59] - R&D expenses increased to CNY 6,647,428.05 from CNY 5,504,816.75, reflecting a growth of approximately 20.7%[63]

广东永顺生物制药股份有限公司 章程 第一章 总则 | 序号 | 发起人名称 | 持股数（万股） | 持股比例 | | --- | --- | --- | --- | | 1 | 广东省现代农业集团有限公司 | 3500.00 | 50.00% | | 2 | 广东省农科集团有限公司 | 2029.20 | 28.99% | | 3 | 广东省农业科学院动物卫生研究所 | 880.00 | 12.57% | | 4 | 蔡建平 | 106.42 | 1.52% | | 5 | 谢丽君 | 56.00 | 0.80% | | 6 | 谢雯 | 54.00 | 0.77% | | 7 | 张健騑 | 49.50 | 0.71% | | 8 | 杨傲冰 | 40.00 | 0.57% | | 9 | 张毓金 | 35.00 | 0.50% | | 10 | 吕殿红 | 31.50 | 0.45% | | 11 | 林克义 | 30.00 | 0.43% | 3 第一条 为维护广东永顺生物制药股份有限公司（以下简称"公司"）、股东和债权 人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司 法》（以下简称"《公 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-034 广东永顺生物制药股份有限公司 关于召开 2022 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2022 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等法律、规范性文件和《公司章程》的 相关规定，会议召开合法合规。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 同一表决权只能选择现场投票和网络投票方式中的一种。同一表决权出现 重复表决的以第一次投票结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2023 年 5 月 16 日 14：30。 2. 本公司董事、监事、高级管理人员。 3. 本公司聘请的律师。 广东君信经纶君厚律师事务所律师。 （七）会议地点 2、网络投票起止时间：2023 年 5 月 15 日 15:00—20 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-027 广东永顺生物制药股份有限公司拟续聘会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 一、拟续聘会计师事务所的基本情况 （一）机构信息 公司拟聘任天健会计师事务所（特殊普通合伙）为 2023 年年度的审计机构。 1.基本信息 会计师事务所名称：天健会计师事务所（特殊普通合伙） 成立日期：2011 年 7 月 18 日 组织形式：特殊普通合伙 注册地址：浙江省杭州市西湖区西溪路 128 号 6 楼 首席合伙人：胡少先 2022 年度末合伙人数量：225 人 2022 年度末签署过证券服务业务审计报告的注册会计师人数：780 人 2021 年收入总额（经审计）：350,100 万元 2021 年审计业务收入（经审计）：317,800 万元 2021 年证券业务收入（经审计）：190, ...

Financial Performance - The company's operating revenue for 2022 was CNY 348,717,555.84, a decrease of 4.07% compared to CNY 363,525,642.57 in 2021[27]. - The net profit attributable to shareholders for 2022 was CNY 86,035,881.94, down 5.81% from CNY 91,342,217.51 in 2021[27]. - The total assets at the end of 2022 amounted to CNY 868,912,246.16, reflecting a growth of 7.38% from CNY 809,181,608.59 at the end of 2021[28]. - The total liabilities increased by 66.45% to CNY 172,771,172.59 in 2022, compared to CNY 103,796,628.70 in 2021[28]. - The company's cash flow from operating activities for 2022 was CNY 69,106,539.37, a decline of 31.38% from CNY 100,703,991.33 in 2021[30]. - The gross profit margin for 2022 was 62.53%, down from 67.43% in 2021[27]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 12.38% for 2022, compared to 13.32% in 2021[27]. - The company reported a basic earnings per share of CNY 0.32 for 2022, a decrease of 3.03% from CNY 0.33 in 2021[27]. - The company reported a total non-recurring profit and loss of ¥10,954,801.97 in 2022, an increase of 55.5% compared to ¥7,074,154.63 in 2021[36]. - The company distributed cash dividends totaling 76.36 million yuan based on a plan to distribute 2.8 yuan per 10 shares[55]. Research and Development - The company holds 24 invention patents and 9 utility model patents, with 19 new veterinary drug certificates obtained[12]. - The company has developed two new veterinary vaccines, but market acceptance is currently low, leading to potential revenue risks[13]. - Research and development expenses amounted to 25.38 million yuan, representing 7.28% of operating revenue, with new veterinary drug certificates and patents obtained during the period[51]. - The company is developing a new multi-valent inactivated vaccine for poultry, aiming to enhance immune protection efficiency and product practicality, with the goal of obtaining new veterinary drug certificates and achieving industrialization[100]. - The company is working on a new bivalent inactivated vaccine for swine influenza (H1N1 and H3N2), utilizing MDCK cell culture, which is expected to contribute positively to the development of swine influenza vaccines[100]. - The company is developing a heat-resistant inactivated vaccine for swine diseases, which aims to simplify immunization procedures and reduce stress and infection risks, thereby improving immune efficacy[100]. - The company is advancing the development of a carbon nanotube-based subunit vaccine for the bass virus, addressing urgent needs in the aquaculture industry and aiming for industrialization[100]. - The company is establishing a gene editing technology and recombinant protein expression techniques to create safer and more effective vaccines against major animal diseases[102]. - The company is focusing on the development of multi-valent vaccines to optimize immunization programs and reduce costs for livestock farmers[117]. Market and Industry Risks - The company faces risks related to fluctuations in the downstream livestock and poultry farming industry, which could impact vaccine demand and overall performance[11]. - The company’s main products include high pathogenic avian influenza vaccines, which are subject to national procurement policy changes[11]. - The company faces risks related to the sustainability of cooperative research and technology introduction partnerships[13]. - The company has implemented effective measures to mitigate environmental impact, but risks remain if compliance with environmental standards is not maintained[13]. - The company’s product demand is closely tied to the livestock industry, with potential performance fluctuations due to natural disasters or major animal disease outbreaks[127]. - The company is a designated producer of inactivated avian influenza vaccines, and changes in national procurement policies could adversely affect profitability[128]. Corporate Governance and Compliance - The company has a total share capital of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[174]. - The board of directors consists of 9 members, with no controlling shareholder or actual controller present[199]. - The company has a supervisory board consisting of 3 members[198]. - The company has a total of 3 independent directors, ensuring governance and oversight[198]. - The company has not reported any significant legal disputes or conflicts of interest involving its directors and senior management during the reporting period[162]. - The commitments made by the company and its major shareholders regarding the avoidance of related party transactions are being fulfilled[159]. - The company has confirmed that all commitments made prior to its listing on the New Third Board are being actively fulfilled[154]. Environmental and Social Responsibility - The company reported a wastewater discharge of 61,627.03 tons per year, with treatment systems in place to manage this waste[116]. - The company donated RMB 36,000 worth of epidemic prevention supplies to the authorities in Yanbian, Jilin Province, during the reporting period[115]. - The company has implemented strict biosecurity measures and management systems to mitigate the risk of biological safety incidents during vaccine production[132]. - Environmental protection measures are in place to comply with regulations, but failure to adhere to increasing standards could lead to operational and reputational damage[141]. Shareholder Information - The top three shareholders of Guangdong Yongshun Biological Pharmaceutical Co., Ltd. are Modern Agricultural Group (39.0638%), Guangdong Agricultural Asset Management Co., Ltd. (19.7081%), and the Animal Health Research Institute of the Guangdong Academy of Agricultural Sciences (11.2676%)[181]. - The total number of shares held by the top ten shareholders is 221,714,894, representing 81.1103% of the total shares[178]. - The company has a total of 3,640 common shareholders, indicating a diverse shareholder base[174]. - The company has ongoing commitments from major shareholders to avoid related party transactions and fund occupation, which are currently being fulfilled[153]. Financial Management - The company has secured loans totaling CNY 20,000,000.00 from China Construction Bank at an interest rate of 3% and CNY 9,900,000.00 from Agricultural Bank of China at the same interest rate[192]. - The company has applied for commercial acceptance bill discount financing totaling CNY 62,313,700.00, with an outstanding balance of CNY 27,542,200.00 as of the reporting period end[193]. - The company has complied with regulatory requirements regarding the management and use of raised funds, with no violations reported[188]. - The company has not changed the intended use of the raised funds, and all funds have been used as planned[189].

证券代码：839729 证券简称：永顺生物 公告编号：2023-029 广东永顺生物制药股份有限公司董事任命公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、任免基本情况 （一）任免的基本情况 根据《公司法》及《公司章程》等有关规定，2023 年 4 月 19 日公司第四届董事会 第十三次会议审议并通过《关于补选公司第四届董事会非独立董事的议案》、《关于补选 公司第四届董事会独立董事的议案》。 提名张建峰先生为公司董事，任职期限自股东大会审议通过之日起至第四届董事会 任期届满为止，本次任免尚需提交股东大会审议，自 2022 年年度股东大会决议通过之 日起生效。上述提名人员持有公司股份 0 股，占公司股本的 0%，不是失信联合惩戒对 象。 提名任涛先生为公司独立董事，任职期限自股东大会审议通过之日起至第四届董事 会任期届满为止，本次任免尚需提交股东大会审议，自 2022 年年度股东大会决议通过 之日起生效。上述提名人员持有公司股份 0 股，占公司股本的 0%，不是失信联合惩戒 对象。 （二）任命原因 ...

本公司董事会于 2023 年 4 月 19 日收到独立董事郭霄峰先生递交的辞职报告，自股 东大会选举产生新任独立董事之日起辞职生效。上述辞职人员持有公司股份 0 股，占公 司股本的 0%，不是失信联合惩戒对象，辞职后不再担任公司其它职务。 （二）辞职原因 郭霄峰先生因在公司连续担任独立董事职务即将满六年，根据《北京证券交易所股 票上市规则（试行）》、《北京证券交易所上市公司持续监管办法（试行）》、《北京证券交 易所上市公司持续监管指引第 1 号—独立董事》及《公司章程》等有关规定，郭霄峰先 生申请辞去公司独立董事职务。 二、上述人员的辞职对公司产生的影响 （一）本次辞职未导致公司董事会成员人数低于法定最低人数，未导致公司监事会成员 人数低于法定最低人数，未导致职工代表监事人数少于监事会成员的三分之一，未导致 董事会中兼任高级管理人员的董事和由职工代表担任的董事人数超过公司董事总数的 二分之一。 证券代码：839729 证券简称：永顺生物 公告编号：2023-038 广东永顺生物制药股份有限公司独立董事辞职公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-032 广东永顺生物制药股份有限公司 关于拟修订《公司章程》公告 是否涉及到公司注册地址的变更：否 除上述修订外，原《公司章程》其他条款内容保持不变，前述内容尚需提交 公司股东大会审议，具体以市场监督管理部门登记为准。 二、修订原因 根据公司实际情况及经营发展需要，拟对营业执照经营范围进行变更，公司 将按相关规定，相应修订《公司章程》的对应条款，并在市场监督管理部门办理 工商变更登记事宜，具体以有关审批机关最终登记为准。本次变更不会导致公司 主营业务发生变更。 三、备查文件 （一）《广东永顺生物制药股份有限公司第四届董事会第十三次会议决议》。 广东永顺生物制药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、修订内容 根据《公司法》及《北京证券交易所股票上市规则（试行）》、《北京证券交 易所上市公司持续监管办法（试行）》等相关规定，公司拟修订《公司章程》的 部分条款，修订对照如下： | 原规定 | 修订后 | | --- | ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-035 广东永顺生物制药股份有限公司 第四届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的参与表决监事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于<2022 年度监事会工作报告>的议案》 1.议案内容： 3.回避表决情况 本议案不涉及回避表决。 本议案尚需提交股东大会审议。 （二）审议通过《关于<2022 年年度报告>及<2022 年年度报告摘要>的议案》 1.议案内容： 详见公司于 2023 年 4 月 20 日在北京证券交易所网站（www.bse.cn）披露的 《2022 年年度报告》（公告编号：2023- 021）及《2022 年年度报告摘要》（公告 编号：2023-022）。 2. ...

中信建投证券股份有限公司 关于广东永顺生物制药股份有限公司 公司治理自查和规范活动的专项核查意见 中信建投证券股份有限公司（以下简称："中信建投证券"、"保荐机构"）作 为广东永顺生物制药股份有限公司（以下简称"永顺生物"或"公司"）向不特 定合格投资者公开发行股票的保荐机构，根据公司治理专项自查及规范活动的相 关要求，结合《公司法》《证券法》《北京证券交易所股票上市规则（试行）》等 法律法规及《公司章程》等内部规章制度，对永顺生物公司治理自查和规范活动 事项开展核查工作并发表专项核查意见如下： 一、上市公司基本情况 永顺生物于 2016 年 11 月 17 日在全国中小企业股份转让系统挂牌，于 2020 年 7 月 27 日公开发行并进入精选层，于 2021 年 11 月 15 日平移至北交所上市。 公司为民营企业，主营业务为兽用生物制品的研发、生产和销售。 公司无控股股东和实际控制人；公司第一大股东为广东省现代农业集团有限 公司，公司第一大股东不存在股份冻结和质押的情况；公司不存在控股子公司持 有公司股份的情形。 三、机构设置情况 截至 2022 年 12 月 31 日，公司董事会共 9 人，其中独立董事 ...